A Study of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With Non-Muscle Invasive Bladder Cancer

Brief description of study

This study is examining how well a new treatment called N-803, combined with a standard treatment called BCG, works compared to just using BCG alone in patients who haven't had BCG before and have a specific type of bladder cancer that hasn't spread into the muscle. There are two groups of patients in the study: one group has a more serious form of the cancer, and the other group has a less serious form. Every patient in the study will get either N-803 and BCG or just BCG through a tube into the bladder for six weeks. After that, the doctors will check how well the treatment is working. If it's going well, some patients will keep getting more treatments to help keep the cancer from coming back. The study will follow patients for about three years to see how they're doing.


Clinical Study Identifier: s24-00373
ClinicalTrials.gov Identifier: NCT02138734
Principal Investigator: Scot Niglio.
Other Investigators: James S Wysock, Minas Platon Economides, Victor Ricardo Adorno Febles, Katie S. Murray, Samir Taneja, Wei Phin Tan, William C Huang, Hank Ng, David R. Wise.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.